Skip to main content

Table 4 Results of MR analyses examining the effect of BMI on molecular risk factors

From: Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis

Outcome

Method

Effect estimate (95% CI)

P value

Total serum cholesterol

IVW

− 0.03 (− 0.06 to 0.01)

1.22 × 10−1

Weighted median

− 0.06 (− 0.11 to − 0.01)

2.98 × 10−2

Weighted mode

− 0.08 (− 0.15 to 0.00)

4.46 × 10−2

MR-Egger

− 0.08 (− 0.16 to 0.00)

3.89 × 10−2

Fasting insulin

IVW

0.17 (0.15 to 0.19)

1.51 × 10−74

Weighted median

0.18 (0.15 to 0.21)

8.51 × 10−31

Weighted mode

0.18 (0.12 to 0.24)

1.88 × 10−9

MR-Egger

0.20 (0.16 to 0.25)

1.30 × 10−16

Total testosterone

IVW

0.08 (0.05 to 0.11)

9.04 × 10−10

Weighted median

0.06 (0.03 to 0.09)

4.95 × 10−4

Weighted mode

− 0.01 (− 0.08 to 0.07)

8.60 × 10−1

MR-Egger

0.02 (− 0.05 to 0.09)

5.23 × 10−1

Bioavailable testosterone

IVW

0.26 (0.23 to 0.29)

9.97 × 10−68

Weighted median

0.24 (0.20 to 0.28)

1.72 × 10−38

Weighted mode

0.09 (0.01 to 0.17)

2.41 × 10−2

MR-Egger

0.16 (0.08 to 0.24)

4.36 × 10−5

SHBG

IVW

− 0.17 (− 0.19 to − 0.16)

4.86 × 10−125

Weighted median

− 0.16 (− 0.18 to − 0.15)

8.85 × 10−77

Weighted mode

− 0.15 (− 0.18 to − 0.12)

8.43 × 10−20

MR-Egger

− 0.13 (− 0.17 to − 0.09)

3.11 × 10−11

  1. BMI is scaled to an SD increase (4.7 kg/m2). Effect estimate represents change in SD (41.7 mg/dL) total serum cholesterol, natural log transformed pmol/L fasting insulin, inverse-normal transformed nmol/L total testosterone, inverse-normal transformed nmol/L bioavailable testosterone and inverse-normal transformed nmol/L SHBG. SHBG sex hormone-binding globulin, IVW inverse-variance weighted